ZLJ-6
ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity.
For research use only. We do not sell to patients.
- CAS No.: 1051931-39-5
- Formula: C13H17N3O6S2
- Molecular Weight:375.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-14164
Zileuton5-Lipoxygenase Inhibitor -
HY-111140
YS121mPGES-1/5-LOX Inhibitor -
HY-119671
BW 755C5-LO/COX Inhibitor -
HY-118480
4-MMPB15-lipoxygenase Inhibitor -
HY-126898
5-LO/mPGES1-IN-15-LO/mPGES-1 Inhibitor -
HY-13219
TepoxalinCyclooxygenase/Lipoxygenase Inhibitor -
HY-14164R
Zileuton (Standard)5-Lipoxygenase Inhibitor -
HY-108456
N-StearoyldopamineBiochemical Reagent -
HY-117008
CAY10589mPGES-1 Inhibitor -
HY-101587
(E)-KME-4PGS Inhibitor -
HY-120502
5-LOX-IN-65-LO Inhibitor -
HY-125975
1-Naphthyl 3,5-dinitrobenzoate5-LOX Inhibitor
Biological Activity
Description
IC50 & Target
|
COX-1 0.73 μM (IC50) |
COX-2 0.31 μM (IC50) |
5-LOX 0.99 μM (IC50) |
In Vitro
ZLJ-6 (3, 10, 30 μM, 6 h) can effectively inhibit the expression of TNF-α-induced monocyte endothelial interaction and adhesion molecules (e-selectin, ICAM-1 and VCAM-1)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVECs
-
Concentration:3, 10, 30 μM
-
Incubation Time:6 h
-
Result:Decreased NF-κB p65 subunit translocation to nucleus dose-dependently.
Inhibited TNF-α-induced IκBα phosphorylation.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1051931-39-5
-
Molecular Weight 375.42
-
Formula C13H17N3O6S2
-
SMILES
CS(=O)(O)=O.CN(C(N)=NC/1=O)C1=C/C2=CC=C(C=C2)S(C)(=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
[1]. Chen L, et al. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. Vascul Pharmacol. 2011 Nov-Dec;55(5-6):135-42. [Content Brief]
[2]. Li L, et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol. 2009 Apr 1;607(1-3):244-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ZLJ-6 Related Classifications
HY-113807 Related Classifications
Powered by Bioz